UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Journal of clinical pharmacology, 2010-07, Vol.50 (7), p.743-753

2010

Volltextzugriff (PDF)

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

Journal of clinical pharmacology, 2011-05, Vol.51 (5), p.687-694

2011

Volltextzugriff (PDF)

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux

Thrombosis research, 2012-04, Vol.129 (4), p.e77-e82

2012

Volltextzugriff (PDF)

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

Thrombosis and haemostasis, 2007-10, Vol.98 (4), p.883-888

2007

Volltextzugriff (PDF)

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers

Thrombosis research, 2015-04, Vol.135 (4), p.594-601

2015

Volltextzugriff (PDF)

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Thrombosis and haemostasis, 2010-09, Vol.104 (3), p.633-641

2010

Volltextzugriff (PDF)

Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin

Thrombosis and haemostasis, 2002-11, Vol.88 (5), p.733-738

2002

Volltextzugriff (PDF)

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

Journal of clinical pharmacology, 2015-11, Vol.55 (11), p.1286-1292

2015

Volltextzugriff (PDF)

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Thrombosis and haemostasis, 2012-05, Vol.107 (5), p.925-934

2012

Volltextzugriff (PDF)

Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat

Shock (Augusta, Ga.), 2002-02, Vol.17 (2), p.159-162

2002

Volltextzugriff (PDF)

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

Thrombosis research, 1995-10, Vol.80 (1), p.99-104

1995

Volltextzugriff (PDF)

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

Thrombosis and haemostasis, 2011-06, Vol.105 (6), p.1080-1090

2011

Volltextzugriff (PDF)

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist

Thrombosis and haemostasis, 2004-12, Vol.92 (6), p.1229-1231

2004

Volltextzugriff (PDF)

A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats

Thrombosis research, 2000-04, Vol.98 (2), p.175-185

2000

Volltextzugriff (PDF)

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults

Thrombosis research, 2010-10, Vol.126 (4), p.e286-e293

2010

Volltextzugriff (PDF)

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model

Thrombosis and haemostasis, 1999-05, Vol.81 (5), p.828-34

1999

Volltextzugriff (PDF)

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates

Circulation (New York, N.Y.), 1995-08, Vol.92 (3), p.485-491

1995

Volltextzugriff (PDF)

A Specific Inhibitor of Factor Xa, DX-9065a, Exerts Effective Protection against Experimental Tumor-Induced Disseminated Intravascular Coagulation in Rats

Thrombosis research, 1999-10, Vol.96 (2), p.135-143

1999

Volltextzugriff (PDF)

DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITIES OF ORALLY ACTIVE COAGULATION FACTOR Xa INHIBITORS

European journal of medicinal chemistry, 1995, Vol.30, p.139s-143s

1995

Volltextzugriff (PDF)

FXa inhibitors : Updates on clinical trial

Nihon Kessen Shiketsu Gakkai shi, 2009, Vol.20 (5), p.527-533

2009

Volltextzugriff (PDF)

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

Blood, 2008-11, Vol.112 (11), p.33-33

2008

Volltextzugriff (PDF)

Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 Groups of Elderly Healthy Subjects

Blood, 2008-11, Vol.112 (11), p.3026-3026

2008

Volltextzugriff (PDF)

選択的活性化血液凝固第X因子阻害薬エドキサバンの研究開発

ファルマシア, 2019, Vol.55(6), pp.549-552

2019

Volltextzugriff (PDF)

First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation

Circulation (New York, N.Y.), 2002-05, Vol.105 (20), p.2385-2391

2002

Volltextzugriff (PDF)

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Clinical pharmacology and therapeutics, 1999-09, Vol.66 (3), p.258-264

1999

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(49)
Mit Volltextzugriff
(58)

Publikationsform

Artikel
(72)

Sprache

Englisch
(67)
Japanisch
(7)

Erscheinungsjahr

n.n

Thema

Science & Technology
(41)
Life Sciences & Biomedicine
(39)
Humans
(27)
Biological And Medical Sciences
(20)
Male
(20)
Cardiovascular System & Cardiology
(18)
Medical Sciences
(18)
Factor Xa Inhibitors
(17)
Peripheral Vascular Disease
(17)
Hematology
(16)
Animals
(11)
Pharmacology. Drug Treatments
(11)
Female
(10)
Pharmacology & Pharmacy
(10)
Anticoagulants - Administration & Dosage
(9)
Molecular Sequence Data
(9)
Rats
(9)
Administration, Oral
(8)
Adult
(8)
Blood. Blood Coagulation. Reticuloendothelial System
(8)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Clinical Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Factor Xa Inhibitor Edoxaban in Healthy Volunteers

Effects of Food on the Pharmacokinetics of Edoxaban, an Oral Direct Factor Xa Inhibitor, in Healthy Volunteers

In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux

Antithrombotic effects of factor Xa inhibition with DU-176b: Phase-I study of an oral, direct factor Xa inhibitor using an ex-vivo flow chamber

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of the Novel Factor Xa Inhibitor DY-807f in Healthy Volunteers

Randomised, parallel-group, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation

Antithrombotic effects of DX-9065a, a direct factor Xa inhibitor: a comparative study in humans versus low molecular weight heparin

Evaluation of regional gastrointestinal absorption of edoxaban using the enterion capsule

Modelling and simulation of edoxaban exposure and response relationships in patients with atrial fibrillation

Factor Xa-inhibitor (DX-9065a) modulates the leukocyte-endothelial cell interaction in endotoxemic rat

Species differences in anticoagulant and anti-Xa activity of DX-9065a, a highly selective factor Xa inhibitor

Effect of edoxaban on markers of coagulation in venous and shed blood compared with fondaparinux

Combined coagulation phase-directed factor Xa inhibition with heparin compounds and DX-9065a - a direct and selective antagonist

A Synthetic Inhibitor of Factor Xa, DX-9065a, Reduces Proliferation of Vascular Smooth Muscle Cells in Vivo in Rats

Comparison of a direct Factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: A randomised controlled trial in healthy elderly adults

DX-9065a, an orally active factor Xa inhibitor, does not facilitate haemorrhage induced by tail transection or gastric ulcer at the effective doses in rat thrombosis model

Antithrombotic effects of orally active synthetic antagonist of activated factor X in nonhuman primates

A Specific Inhibitor of Factor Xa, DX-9065a, Exerts Effective Protection against Experimental Tumor-Induced Disseminated Intravascular Coagulation in Rats

DESIGN, SYNTHESIS AND BIOLOGICAL ACTIVITIES OF ORALLY ACTIVE COAGULATION FACTOR Xa INHIBITORS

FXa inhibitors : Updates on clinical trial

Randomized, Parallel Group, Multicenter, Multinational Study Evaluating Safety of DU-176b Compared with Warfarin in Subjects with Non-Valvular Atrial Fibrillation

Study of Coagulation and Platelets Response in An Open Label Randomised Non Treatment and Active Controlled (Dalteparin, Ximelagatran and DU- 176b) in 4 Groups of Elderly Healthy Subjects

選択的活性化血液凝固第X因子阻害薬エドキサバンの研究開発

First experience with direct factor Xa inhibition in patients with stable coronary disease: A pharmacokinetic and pharmacodynamic evaluation

Tolerability, pharmacokinetics, and pharmacodynamics of DX-9065a, a new synthetic potent anticoagulant and specific factor Xa inhibitor, in healthy male volunteers

Suchergebnisse filtern